Skip to content
Artwork for The Longevity Podcast: Alzheimer's and Brain Health Research
Health & FitnessMedicineScienceLife Sciences

The Longevity Podcast: Alzheimer's and Brain Health Research

Dung Trinh

AI-hosted deep dives into the latest Alzheimer's, dementia and brain health research, curated by Dr. Dung Trinh. Each episode breaks down a recent study or topic, such as diet, sleep, exercise, heart health, biomarkers, early detection and new treatments. We explain what the science says and what it may mean for staying sharp as we age.

Episodes are discussions generated with AI hosts. Every episode cites its sources so you can read the original research yourself. This podcast is for education only and is not medical advice. Talk with your doctor about your own health.

Play
  • 72 episodes
  • Avg 31 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Today · 19 min

    Brain Health: Can 40 Hz Light and Sound Help Clear Amyloid in Mice?

    Send us Fan Mail Can flickering light and sound at 40 beats per second help the brain clear out amyloid, the protein that builds up in Alzheimer's disease? In this episode we look at a study in an Alzheimer's mouse model that found 40 Hz light-and-sound stimulation increased the flow of cleaning fluid through the brain (the glymphatic system), changed water channels on support cells, widened drainage vessels around the brain, and lowered amyloid, with a type of brain cell called VIP interneurons helping drive the effect. When the clearance system was blocked, the amyloid reduction went away. These results are in mice and are not proven in people. This is an educational discussion of a research paper, not medical advice. Source: Murdock MH, Yang C-Y, Sun N, et al., Tsai L-H. "Multisensory gamma stimulation promotes glymphatic clearance of amyloid." Nature 627, 149–156 (2024). https://doi.org/10.1038/s41586-024-07132-6 (PMC10917684, https://pmc.ncbi.nlm.nih.gov/articles/PMC10917684/). Open access under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Yesterday · 20 min

    Brain Health: CTAD 2026 – A New Blood Test for Advanced Alzheimer's Tau Tangles

    Send us Fan Mail Conference news from CTAD 2026 (Clinical Trials on Alzheimer's Disease, Boston). Researchers led by Nicholas Ashton, PhD, of Banner Sun Health Research Institute presented a new blood test for eMTBR-tau, a marker of the tau tangles seen in advanced Alzheimer's disease, also published in JAMA. In 728 people across autopsy and tau PET studies, levels were 25- to 60-fold higher at the most advanced tangle stages and closely matched a more complex lab method. We walk through what this means and the caveats: a one-time snapshot study, limited sensitivity at early stages, and a research tool that is not yet available to patients. Sources: JAMA: https://jamanetwork.com/journals/jama/fullarticle/2856953 PubMed: https://pubmed.ncbi.nlm.nih.gov/43038566/ Medscape Medical News: https://www.medscape.com/viewarticle/blood-test-may-offer-new-window-alzheimers-progression-2026a100195v CTAD 2026: https://www.ctad-alzheimer.com/ This episode was generated with AI from a written summary of public reports. It is an educational news discussion and is not medical advice. Talk with your own doctor about any health decisions. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Yesterday · 22 min

    Brain Health: Can Blood Tests Track Alzheimer's and Vessel Damage?

    Send us Fan Mail Many older adults have both Alzheimer's changes and damage to the brain's small blood vessels. In this episode we look at a study of people with normal memory or mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative, which asked whether four blood markers (GFAP, neurofilament light, p-tau217, and the amyloid 42/40 ratio) track white matter changes, hippocampal shrinkage, amyloid build-up, and memory decline over time. Higher GFAP and p-tau217 were linked to more brain changes and faster decline, and p-tau217 helped predict who with Alzheimer's features went on to develop small vessel disease. These are associations from an observational study, not proof of cause. This is an educational discussion of a research paper, not medical advice. Source: Yang J, Zhao X, Liu Y, Cai Y, Fan Y, for the Alzheimer's Disease Neuroimaging Initiative. "Associations of plasma biomarkers with longitudinal co-pathologies in Alzheimer's disease and cerebral small vessel disease comorbidity." The Journal of Prevention of Alzheimer's Disease 13 (2026) 100449. https://doi.org/10.1016/j.tjpad.2025.100449 (PMC12869035). Open access under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Friday · 22 min

    Brain Health: CTAD 2026 – Two-Year Results for the Tau-Lowering Drug Diranersen

    Send us Fan Mail Conference news from CTAD 2026 (Clinical Trials on Alzheimer's Disease, Boston). Biogen presented two-year data from the Phase 2 CELIA study of diranersen (BIIB080), an investigational antisense therapy, discovered by Ionis, that lowers the brain's production of tau. In the open-label extension, people on 60 mg twice yearly showed 38% slower decline on CDR-SB at two years (a 1.09-point difference) compared with former placebo participants, up from 26% at 18 months. We walk through the numbers, the safety findings, and the caveats: the study missed its primary dose-response endpoint, the two-year comparison is not fully randomized, the results are not yet peer reviewed, and a Phase 3 trial is still needed. Sources: Ionis/Biogen announcement: https://markets.ft.com/data/announce/detail?dockey=600-202611171645BIZWIRE_USPRX____20261117_BW852253-1 MedPage Today: https://www.medpagetoday.com/meetingcoverage/ctad/123956 Clinical Trials Arena: https://www.clinicaltrialsarena.com/news/biogen-two-year-phase-ii-data-diranersen-ad/ ClinicalTrials.gov NCT05399888: https://clinicaltrials.gov/study/NCT05399888 CTAD 2026: https://www.ctad-alzheimer.com/ This episode was generated with AI from a written summary of public reports. It is an educational news discussion and is not medical advice. Talk with your own doctor about any treatment decisions. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Friday · 20 min

    Brain Health: Which Everyday Risk Factors Change the Aging Brain?

    Send us Fan Mail Which risk factors are tied to changes in the brain years before memory problems appear? In this episode we unpack a Swedish study that followed 494 adults with normal thinking for about four years with repeated MRI and PET scans. Higher blood pressure, high cholesterol, heart disease, smoking and less education were linked to faster growth of white matter changes (signs of small blood vessel damage). The APOE e4 gene, diabetes and higher depression scores were linked to faster amyloid buildup, and lower body weight to faster tau buildup. These are associations from an observational study, not proof of cause. This is an educational discussion of a research paper, not medical advice. Source: Glans I, Mattsson-Carlgren N, Strandberg O, Stomrud E, Ossenkoppele R, van Westen D, Spotorno N, Hansson O, Palmqvist S. "Associations of modifiable and non-modifiable risk factors with longitudinal white matter hyperintensities, amyloid-β and tau - a prospective cohort study." The Journal of Prevention of Alzheimer's Disease 13 (2026) 100448. https://doi.org/10.1016/j.tjpad.2025.100448 (PMC12869030). Open access under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/). Audio discussion generated with AI hosts from the article. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Thursday · 21 min

    Brain Health: CTAD 2026 – Five-Year Results for the Alzheimer's Drug Lecanemab

    Send us Fan Mail Conference news from CTAD 2026 (Clinical Trials on Alzheimer's Disease, Boston). Eisai and Biogen presented five-year data for lecanemab (Leqembi) from the Clarity AD study and its open-label extension, in which 351 people received continuous treatment for five years. Compared with outside natural-history data from ADNI, the treated group showed 2.05 points less worsening on CDR-SB at five years, and in a low-tau subgroup 62% had improved CDR-SB scores from baseline. We walk through the numbers, the ARIA safety data by year, and the caveats: after 18 months there was no placebo group, the comparisons use external cohorts, and the results have not yet been peer reviewed. Sources: Eisai and Biogen announcement: https://www.globenewswire.com/news-release/2026/11/16/3404222/0/en/new-five-year-lecanemab-data-from-clarity-ad-study-long-term-extension-presented-at-ctad-2026.html BioArctic announcement: https://news.cision.com/bioarctic/r/five-year-data-of-continuous-leqembi--treatment-show-increasing-benefit-over-time,c4425299 ClinicalTrials.gov NCT03887455: https://clinicaltrials.gov/study/NCT03887455 CTAD 2026: https://www.ctad-alzheimer.com/ This episode was generated with AI from a written summary of public reports. It is an educational news discussion and is not medical advice. Talk with your own doctor about any treatment decisions. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Thursday · 22 min

    Brain Health: How Tau Could Change the Way Alzheimer's Is Diagnosed

    Send us Fan Mail Alzheimer's disease has two key hallmarks in the brain: amyloid plaques and tau tangles. Tau tracks closely with nerve cell loss and memory decline, and it is now measurable with blood tests, spinal fluid tests and tau PET scans. In this episode we unpack an international review on how a growing focus on tau could reshape the patient journey: earlier diagnosis and staging, tracking how the disease is changing, tau-targeting drugs still in development, and what clinics and health systems may need to prepare, along with the open questions that remain. This is an educational discussion of a research paper, not medical advice. Source: Mummery CJ, Chen Li-Hsian C, Lasagna-Reeves CA, Ossenkoppele R, Rowe CC, Scharre DW, Wang H, Kyaga S, Cummings JL. "Tau in Alzheimer's disease: Shaping the future patient journey." The Journal of Prevention of Alzheimer's Disease 13 (2026) 100447. https://doi.org/10.1016/j.tjpad.2025.100447 (PMC12869042). Open access under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/). Audio discussion generated with AI hosts from the article. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Wednesday · 24 min

    Brain Health: CTAD 2026 – Phase 3 Results for a 40Hz Light and Sound Device

    Send us Fan Mail Conference news from CTAD 2026 (Clinical Trials on Alzheimer's Disease, Boston). Dr. Marwan Sabbagh of Barrow Neurological Institute presented 12-month results of HOPE, a Phase 3 sham-controlled trial of Spectris, an investigational at-home headset from Cognito Therapeutics that delivers 40Hz light and sound, in 673 people with mild-to-moderate Alzheimer's disease. The trial did not meet its primary endpoint in the overall population, and the moderate group showed no benefit. A prespecified mild-disease subgroup showed nominal slowing on some measures, including 47% on CDR-SB and 56% on daily function, but these results were not adjusted for multiple comparisons. We walk through the design, the numbers, the safety data, and the caveats: these are preliminary conference results, not yet peer reviewed, and the device is not FDA-cleared or authorized for Alzheimer's disease. Sources: Cognito announcement: https://www.businesswire.com/news/home/20261116639625/en/ NeurologyLive report: https://www.neurologylive.com/view/spectris-misses-primary-end-point-pivotal-hope-trial-alzheimer-disease New York Times report: https://www.nytimes.com/2026/11/16/well/cognito-spectris-alzheimers-headset-device.html ClinicalTrials.gov NCT05637801: https://clinicaltrials.gov/study/NCT05637801 CTAD 2026: https://www.ctad-alzheimer.com/ This episode was generated with AI from a written summary of public reports. It is an educational news discussion and is not medical advice. Talk with your own doctor about any treatment decisions. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Wednesday · 5 min

    Brain Health: Can Neck Surgery Help the Brain Clear Its Waste?

    Send us Fan Mail Every night, the brain flushes out metabolic waste through the glymphatic system and meningeal lymphatic vessels that drain into lymph nodes in the neck. As we age, these pathways can slow down. In this episode we unpack a systematic review from Nantes University Hospital on how this clearance system works and on early, exploratory reports of deep cervical lymphatic surgery (lymphatico-venous anastomosis) in Alzheimer's disease: just 30 patients across a handful of small, mostly uncontrolled studies with short follow-up, plus the risks the authors flag. The evidence is preliminary. This is an educational discussion of a research paper, not medical advice. Source: Lahmar T, Thuau F, Pinard G, Boutoleau-Bretonniere C, Perrot P, Lancien U. "Brain lymphatic drainage pathways, deep cervical lymphatic surgery, and current insights: A systematic review." The Journal of Prevention of Alzheimer's Disease 13 (2026) 100335. https://doi.org/10.1016/j.tjpad.2025.100335 (PMC12811783). Open access under the CC BY 4.0 license (http://creativecommons.org/licenses/by/4.0/). Audio discussion generated with AI hosts from the article. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Tuesday · 20 min

    Brain Health: CTAD 2026 – Phase 3 Results for the Oral Alzheimer's Drug AR1001

    Send us Fan Mail Conference news from CTAD 2026 (Clinical Trials on Alzheimer's Disease, Boston). On the meeting's opening day, Dr. Sharon Sha of Stanford presented 52-week results of POLARIS-AD, a Phase 3 trial of AR1001 (mirodenafil), an investigational once-daily oral PDE5 inhibitor from AriBio, in 1,535 people with early Alzheimer's disease. The pre-specified primary goal was met in the group not taking standard Alzheimer's medicines (0.44-point difference on CDR-SB), but not in the full trial population. We walk through the design, the numbers, the safety data, and the caveats: these are preliminary conference results, not yet peer reviewed, and the drug is not approved. Sources: ChosunBiz report on the CTAD presentation: https://biz.chosun.com/jp/jp-science/2026/11/17/ALDRR3S6TBHMRKROAKV3G5A5TA/ AriBio announcement: https://www.einpresswire.com/article/955172840 ClinicalTrials.gov NCT05531526: https://clinicaltrials.gov/study/NCT05531526 CTAD 2026: https://www.ctad-alzheimer.com/ This episode was generated with AI from a written summary of public reports. It is an educational news discussion and is not medical advice. Talk with your own doctor about any treatment decisions. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Tuesday · 16 min

    Brain Health: Can a Brain MRI Predict How Alzheimer's Treatment Goes?

    Send us Fan Mail Can a brain scan taken before Alzheimer's treatment begins hint at how things will go? This episode walks through a real-world study of 161 patients starting anti-amyloid antibody treatment at a Tokyo dementia center. Researchers looked at whether shrinkage in the brain's memory region and tiny bleeds seen on MRI before treatment were linked to later changes in thinking and daily function, and to the brain-swelling and bleeding side effects called ARIA, and what pre-treatment MRI might add for patients and doctors. Source: Kujuro Y, et al. "Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center." J Prev Alzheimers Dis. 2026;13:100686. https://doi.org/10.1016/j.tjpad.2026.100686. Licensed CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated discussion adapted from the article and is not medical advice. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • Monday · 16 min

    Brain Health: Can Medicines After a Stroke Protect Your Memory?

    Send us Fan Mail After a stroke or mini-stroke, the risk of memory problems and dementia goes up. This episode walks through a new systematic review that pulled together studies of medicines given after stroke or TIA to see whether any of them lowered the risk of cognitive decline or dementia, what the evidence actually shows, and what questions remain for researchers and families. Source: Rosenau C, et al. "Pharmacological interventions for reducing the risk of cognitive decline and dementia after stroke/transient ischemic attack: A systematic review." J Prev Alzheimers Dis. 2026;13(10):100680. https://doi.org/10.1016/j.tjpad.2026.100680. Licensed CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated discussion adapted from the article and is not medical advice. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • November 14 · 20 min

    Brain Health: Can the Way You Speak Predict Dementia?

    Send us Fan Mail Could a short recording of everyday speech help estimate how soon someone with mild cognitive impairment might develop dementia? This episode looks at a study from a Barcelona memory clinic where people with MCI completed a brief spontaneous speech task, and computers extracted language and voice features to predict their time to dementia, compared with standard memory and thinking tests. Source: Hinojosa-Calleja A, Calm B, et al. "Survival analysis of spontaneous speech for predicting mild cognitive impairment-to-dementia conversion." J Prev Alzheimers Dis. 2026;13(10):100692. https://doi.org/10.1016/j.tjpad.2026.100692. Licensed CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated discussion adapted from the article and is not medical advice. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 30 · 22 min

    Brain Health: Does High-Dose DHA From Fish Oil Reach the Aging Brain?

    Send us Fan Mail In a two-year randomized, double-blind, placebo-controlled trial, 365 adults aged 55 to 80 at higher risk for dementia took 2,000 mg of DHA, an omega-3 fatty acid found in fish oil, or a placebo each day. DHA levels in the fluid around the brain rose by about 17%, but the trial found no benefit to memory or thinking. We look at what the study measured, what it found, and its limitations, including that about 38% of participants dropped out. This episode is for education only and is not medical advice. Source: Yassine HN et al. "CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial." eBioMedicine 2026;129:106316. https://doi.org/10.1016/j.ebiom.2026.106316 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 28 · 21 min

    Brain Health: Frailty as a Compass for Alzheimer's Care

    Send us Fan Mail Two people can be the same age but have very different reserves to handle illness and treatment. In this editorial, Dr. Nicholas Vogt and Dr. Dae Hyun Kim look at why frailty matters as more older adults are evaluated for new anti-amyloid Alzheimer's therapies. They build on an expert-panel proposal to use frailty as a "clinical compass" that guides care rather than a reason to exclude people, with fuller assessment, team discussion, and reassessment over time. We talk about the open questions, from what doctors should do differently once frailty is found to why future studies and registries need to measure it. This episode is for education only and is not medical advice. Source: Vogt NM, Kim DH. "Frailty in the anti-amyloid era: an opportunity to individualize care." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100682. DOI: https://doi.org/10.1016/j.tjpad.2026.100682. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 27 · 21 min

    Brain Health: Can 40 Hz Light and Sound in VR Help Alzheimer's?

    Send us Fan Mail Can flickering light and sound at 40 beats per second, delivered through a virtual reality headset, safely engage the brain in early Alzheimer's disease? In this small single-session feasibility study, 11 older adults with mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia explored three immersive VR environments with 40 Hz audiovisual stimulation and a sham comparison while their brain waves were recorded by EEG. Everyone finished the session with no serious side effects, the 40 Hz stimulation produced clearly stronger brain responses at that frequency than sham, and in early exploratory tests video-word pairs learned during 40 Hz stimulation were remembered better than those learned during sham. We talk about what this early study can and can't tell us, and what longer at-home studies would need to show. Source: Reis C, Hainke L, Headley G, Navarro S, Zanto TP, Certain R. "Feasibility of immersive 40 Hz gamma sensory stimulation in early-stage Alzheimer's disease." The Journal of Prevention of Alzheimer's Disease, 2026;13(10):100679. DOI: https://doi.org/10.1016/j.tjpad.2026.100679. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 26 · 44 min

    Brain Health: Dementia Risk and Racial Gaps in Older Americans

    Send us Fan Mail How common is dementia among older Americans, and who carries the heaviest burden? This study used the 2023 National Health and Aging Trends Study, a nationally representative sample of 7,574 older adults, to estimate probable and possible dementia and the factors tied to it. Older age, less education, stroke, falls, and depression or anxiety went with higher odds, while vision correction and hearing aid use went with lower odds. The gaps were striking: Hispanic adults 85 and older had about a 60% predicted probability of probable dementia versus about 35% for non-Hispanic White adults, and chewing or swallowing problems mattered far more for Hispanic adults. We talk about what the study can and can't show, and why hearing, dental, and mental health care may matter for brain health. Source: Lee YS, Cruz JA, Kabakibi M, Moore A, Lee JA, Jun HJ. "Prevalence, risk factors, and racial disparities in probable and possible dementia: the national health and aging trends study." The Journal of Prevention of Alzheimer's Disease, 2026;13(10):100676. DOI: https://doi.org/10.1016/j.tjpad.2026.100676. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 25 · 23 min

    Brain Health: What's Good for the Heart Is Good for the Brain

    Send us Fan Mail Can your heart-risk score hint at how fast your memory and thinking may change? In this editorial, Dr. Maileen Ulep looks at a rural U.S. study (Project FRONTIER) that used the American Heart Association's PREVENT equations to estimate 10-year cardiovascular risk. Each 10-point rise in that risk went with about one extra point of yearly decline on a standard memory and thinking test, especially in attention and delayed memory. We talk about why rural communities are understudied, what the study can and can't show, and why checking heart risk early in life may be one of the best ways to protect brain health. Source: Ulep MG. "What's good for the heart is good for the brain? Evidence from a rural cohort on the longitudinal relationship between atherosclerotic cardiovascular disease risk and cognitive decline." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100672. DOI: https://doi.org/10.1016/j.tjpad.2026.100672. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 24 · 1 hr 5 min

    Frailty and Alzheimer's: Why Biological Age Matters for New Therapies

    Send us Fan Mail New disease-modifying therapies are changing Alzheimer's care, but the trials behind them rarely measured frailty, the loss of physical reserve that is common in older adults with Alzheimer's. In this review, a group of European geriatricians and neurologists explains what frailty is and how it's measured, why it may affect safety and benefit, and the open questions and ethical grey zones. They propose a frailty-informed, step-by-step pathway, starting with simple screening in primary care, to guide more individualized decisions. Frailty, they stress, is not a simple yes-or-no for treatment. This episode is for education only, not medical advice. Source: Bellelli G, Brignoli O, Canevelli M, et al. "Integrating frailty into decision-making for disease-modifying therapies in Alzheimer's disease: a proposed expert-opinion based approach." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100666. DOI: https://doi.org/10.1016/j.tjpad.2026.100666. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • October 23 · 19 min

    Omega-3 and Memory Decline: The Study Authors Respond to Critics

    Send us Fan Mail Did omega-3 supplement use really go along with faster memory decline in older adults? After two letters challenged their ADNI-based study, study authors Liao and Wang reply point by point: how supplement use was measured, which confounders were and weren't covered, why their result differs from earlier work on the same data, and what their brain-scan findings can and can't show. Their bottom line: the link is a signal worth checking, not proof of harm and not a reason to stop supplements or change guidelines. We walk through the back-and-forth and what it teaches about reading nutrition and brain-health research. Source: Liao ZB, Wang YR. "Response to two letters on omega-3 supplementation and cognitive decline." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100662. DOI: https://doi.org/10.1016/j.tjpad.2026.100662. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
Showing 1–20 of 72 episodes